5-HT2A mediated plasticity as a target in major depression: a narrative review connecting the dots from neurobiology to cognition and psychology
arXiv Preprint Archive – July 16, 2020
Source: arXiv
Summary
Recent breakthroughs in depression treatment reveal how psychedelics and ketamine work through a fascinating brain mechanism: they promote neural plasticity and boost a key growth factor called BDNF. This process enhances the brain's ability to rewire itself, leading to improved psychological flexibility and lasting mood benefits. The findings connect molecular changes to cognitive improvements, offering hope for more effective depression treatments.
Abstract
As the world's first primary morbidity factor, depression has a considerable impact on both an individual as well as a societal level. despite their discovery several decades ago, classical antidepressants have been shown to provide limited benefits against this condition. However, substances such as ketamine and psychedelics have recently shown promising results and even received the grade of Breakthrough therapy for this indication. The accurate mechanisms of action underlying the efficacy of these substances are still to be defined, but some similarities appear to be shared on different levels across these substances. These include their structural, functional and behavioral plasticity promoting abilities, as well as their capacity to promote Brain-Derived Neurotrophic Factor overexpression, which seems to constitute a key element underlying their immediate and long-lasting action. From this observation, the present review aims to examine and connect the pharmacological pathways involved in these therapies to the neurobiological, cognitive and psychological responses that could be shared by both 5-HT2AR agonists and NMDA antagonists. It is suggested that BDNF overexpression resulting from mTOR activation mediates both structural and functional plasticity, resulting in connectivity changes among high-level cognitive networks such as the Default Mode Network, finally leading to an increased and long-lasting psychological flexibility. Connecting these pieces of evidence could provide insights about their precise mechanisms of action and help researchers to develop biomarkers for antidepressant response. If the hypotheses suggested in this review are verified by further trials, they could also constitute a starting point to developing safer and more efficient antidepressants, as well as provide information about the interactions that exist between different neurotransmitters systems.